1 March 2019 - The March 2019 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The March issue of the Schedule includes a number of new/revised listings:

• Bictegravir sodium with emtricitabine and tenofovir alafenamide fumarate (Biktarvy) - new combination product
• Glycomacropeptide and essential amino acids with vitamins and minerals (PKU Glytactin RTD 15 Lite) - new formulation
• Guanfacine hydrochloride (Intuniv) - new indication
  
• Hypromellose (In a Wink Moisturising, Genteal)
• Ixekizumab (Taltz) - new indication
  
• Lenvatinib mesylate (Lenvima) - new indication
  
• Nivolumab (Opdivo) - new indication
  
• Pembrolizumab (Keytruda) - new indication
  
• Tiotropium hydrogen bromide (Spiriva) - new indication
  
• Venetoclax (Venclexta) - new medicine
  

Read summary of changes